{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:43:10Z","timestamp":1774010590358,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007489","name":"Bausch + Lomb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40123-021-00401-x","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T16:03:01Z","timestamp":1635350581000},"page":"859-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Review of Loteprednol Etabonate 0.5%\/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-4590","authenticated-orcid":false,"given":"Francis S.","family":"Mah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Karpecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"5","key":"401_CR1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14656561003667532","volume":"11","author":"TL Comstock","year":"2010","unstructured":"Comstock TL, Holland EJ. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opin Pharmacother. 2010;11(5):843\u201352.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"401_CR2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00003226-200307000-00009","volume":"22","author":"DF Sweeney","year":"2003","unstructured":"Sweeney DF, Jalbert I, Covey M, et al. Clinical characterization of corneal infiltrative events observed with soft contact lens wear. Cornea. 2003;22(5):435\u201342.","journal-title":"Cornea"},{"issue":"Suppl 2","key":"401_CR3","first-page":"S1","volume":"44","author":"CHL Lim","year":"2018","unstructured":"Lim CHL, Stapleton F, Mehta JS. Review of contact lens-related complications. Eye Contact Lens. 2018;44(Suppl 2):S1\u201310.","journal-title":"Eye Contact Lens"},{"issue":"3","key":"401_CR4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/antibiotics8030088","volume":"8","author":"A Tavakoli","year":"2019","unstructured":"Tavakoli A, Flanagan JL. The case for a more holistic approach to dry eye disease: is it time to move beyond antibiotics? Antibiotics (Basel). 2019;8(3):88.","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"401_CR5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/ICO.0000000000001982","volume":"38","author":"EJ Holland","year":"2019","unstructured":"Holland EJ, Fingeret M, Mah FS. Use of topical steroids in conjunctivitis: a review of the evidence. Cornea. 2019;38(8):1062\u20137.","journal-title":"Cornea"},{"key":"401_CR6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","volume":"176","author":"HS Barnebey","year":"2017","unstructured":"Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed Travoprost 0.004%\/Timolol 05% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"401_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.17925\/USOR.2020.13.1.18","volume":"13","author":"C Matossian","year":"2020","unstructured":"Matossian C. Noncompliance with prescribed eyedrop regimens among patients undergoing cataract surgery\u2014prevalence, consequences, and solutions. Touch Ophthalmol. 2020;13(1):18\u201322.","journal-title":"Touch Ophthalmol"},{"key":"401_CR8","unstructured":"Zylet [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2019."},{"key":"401_CR9","doi-asserted-by":"publisher","first-page":"789623","DOI":"10.1155\/2012\/789623","volume":"2012","author":"TL Comstock","year":"2012","unstructured":"Comstock TL, DeCory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623. https:\/\/doi.org\/10.1155\/2012\/789623.","journal-title":"Int J Inflam."},{"issue":"4","key":"401_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14656566.2018.1439920","volume":"19","author":"TL Comstock","year":"2018","unstructured":"Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018;19(4):337\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"401_CR11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12325-016-0315-8","volume":"33","author":"JD Sheppard","year":"2016","unstructured":"Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33(4):532\u201352.","journal-title":"Adv Ther"},{"issue":"5","key":"401_CR12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1172\/JCI111599","volume":"74","author":"S Manabe","year":"1984","unstructured":"Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest. 1984;74(5):1803\u201310.","journal-title":"J Clin Invest"},{"issue":"2","key":"401_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0039-6257(87)90103-2","volume":"32","author":"KR Wilhelmus","year":"1987","unstructured":"Wilhelmus KR, Gilbert ML, Osato MS. Tobramycin in ophthalmology. Surv Ophthalmol. 1987;32(2):111\u201322.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"401_CR14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003495-200161020-00003","volume":"61","author":"PY Robert","year":"2001","unstructured":"Robert PY, Adenis JP. Comparative review of topical ophthalmic antibacterial preparations. Drugs. 2001;61(2):175\u201385.","journal-title":"Drugs"},{"key":"401_CR15","doi-asserted-by":"crossref","unstructured":"Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981\u20131982;1(9):523\u201334.","DOI":"10.3109\/02713688109069178"},{"issue":"5","key":"401_CR16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/112067210501500504","volume":"15","author":"K Kernt","year":"2005","unstructured":"Kernt K, Martinez MA, Bertin D, International Tobrex2x Group (Eu), et al. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. Eur J Ophthalmol. 2005;15(5):541\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"401_CR17","first-page":"177","volume":"1","author":"M Abelson","year":"2007","unstructured":"Abelson M, Protzko E, Shapiro A, Garces-Soldana A, Bowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol. 2007;1(2):177\u201382.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"401_CR18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bjo.2006.103556","volume":"91","author":"I Cochereau","year":"2007","unstructured":"Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol. 2007;91(4):465\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"401_CR19","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1167\/iovs.06-1413","volume":"48","author":"E Protzko","year":"2007","unstructured":"Protzko E, Bowman L, Abelson M, Shapiro A, AzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48(8):3425\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"401_CR20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/112067219400400102","volume":"4","author":"PA Bloom","year":"1994","unstructured":"Bloom PA, Leeming JP, Power W, Laidlaw DA, Collum LM, Easty DL. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. Eur J Ophthalmol. 1994;4(1):6\u201312.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"401_CR21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF02849993","volume":"24","author":"SS Rhee","year":"2007","unstructured":"Rhee SS, Mah FS. Comparison of tobramycin 0.3%\/dexamethasone 0.1% and tobramycin 03%\/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. Adv Ther. 2007;24(1):60\u20137.","journal-title":"Adv Ther"},{"issue":"8","key":"401_CR22","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1185\/03007990802231981","volume":"24","author":"JD Bartlett","year":"2008","unstructured":"Bartlett JD, Holland EJ, Usner DW, Paterno MR, Comstock TL. Tolerability of loteprednol\/tobramycin versus dexamethasone\/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study. Curr Med Res Opin. 2008;24(8):2219\u201327.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"401_CR23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/ICO.0b013e31815873c7","volume":"27","author":"EJ Holland","year":"2008","unstructured":"Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol\/tobramycin vs dexamethasone\/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27(1):50\u20135.","journal-title":"Cornea"},{"issue":"1","key":"401_CR24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079908X253898","volume":"24","author":"EM White","year":"2008","unstructured":"White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin. 2008;24(1):287\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"401_CR25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1185\/03007995.2012.659723","volume":"28","author":"M Chen","year":"2012","unstructured":"Chen M, Gong L, Sun X, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin. 2012;28(3):385\u201394.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"401_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11596320-000000000-00000","volume":"14","author":"TL Comstock","year":"2012","unstructured":"Comstock TL, Paterno MR, Bateman KM, DeCory HH, Gearinger M. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Pediatr Drugs. 2012;14(2):119\u201330.","journal-title":"Pediatr Drugs"},{"issue":"2","key":"401_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09273948.2015.1115879","volume":"25","author":"TL Comstock","year":"2017","unstructured":"Comstock TL, DeCory HH. Loteprednol etabonate 0.5%\/tobramycin 0.3% compared with dexamethasone 0.1%\/tobramycin 0.3% for the treatment of blepharitis. Ocul Immunol Inflamm. 2017;25(2):267\u201374.","journal-title":"Ocul Immunol Inflamm"},{"key":"401_CR28","first-page":"3467620","volume":"2021","author":"L Zhao","year":"2021","unstructured":"Zhao L, Sun YJ, Pan ZQ. Topical steroids and antibiotics for adult blepharokeratoconjunctivitis (BKC): A meta-analysis of randomized clinical trials. J Ophthalmol. 2021;2021:3467620.","journal-title":"J Ophthalmol"},{"issue":"8","key":"401_CR29","first-page":"414","volume":"62","author":"JE Deom","year":"2021","unstructured":"Deom JE, Cavet ME, Sanfilippo CM, DeCory HH. In vitro potency of tobramycin against common bacterial pathogens implicated in blepharitis. Invest Ophthalmol Vis Sci. 2021;62(8):414.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"401_CR30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/02713689509033519","volume":"14","author":"LS Engel","year":"1995","unstructured":"Engel LS, Callegan MC, Hobden JA, Reidy JJ, Hill JM, O\u2019Callaghan RJ. Effectiveness of specific antibiotic\/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995;14(3):229\u201334.","journal-title":"Curr Eye Res"},{"key":"401_CR31","first-page":"65","volume":"40","author":"U Pleyer","year":"2002","unstructured":"Pleyer U, Sherif Z. Corticosteroids in ophthalmology. Ernst Schering Res Found Workshop. 2002;40:65\u201381.","journal-title":"Ernst Schering Res Found Workshop"},{"issue":"1","key":"401_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33\u201355.","journal-title":"Drug Saf"},{"issue":"4","key":"401_CR33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","volume":"92","author":"CE Pavesio","year":"2008","unstructured":"Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92(4):455\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"401_CR34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/OPX.0b013e3180485d5f","volume":"84","author":"F Stapleton","year":"2007","unstructured":"Stapleton F, Keay L, Jalbert I, Cole N. The epidemiology of contact lens related infiltrates. Optom Vis Sci. 2007;84(4):257\u201372.","journal-title":"Optom Vis Sci"},{"issue":"5","key":"401_CR35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/1120672119885050","volume":"30","author":"MG Musleh","year":"2020","unstructured":"Musleh MG, Bokre D, Dahlmann-Noor AH. Risk of intraocular pressure elevation after topical steroids in children and adults: a systematic review. Eur J Ophthalmol. 2020;30(5):856\u201366.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"401_CR36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/02713689209001808","volume":"11","author":"N Bodor","year":"1992","unstructured":"Bodor N, Wu WM. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res. 1992;11(6):525\u201330.","journal-title":"Curr Eye Res"},{"issue":"3","key":"401_CR37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archopht.117.3.361","volume":"117","author":"P Bhattacherjee","year":"1999","unstructured":"Bhattacherjee P, Paterson CA, Spellman JM, Graff G, Yanni JM. Pharmacological validation of a feline model of steroid-induced ocular hypertension. Arch Ophthalmol. 1999;117(3):361\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"401_CR38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40123-013-0020-5","volume":"2","author":"U Pleyer","year":"2013","unstructured":"Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55\u201372.","journal-title":"Ophthalmol Ther"},{"key":"401_CR39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcrs.2010.10.051","volume":"37","author":"DF Chang","year":"2011","unstructured":"Chang DF, Tan JJ, Tripodis Y. Risk factors for steroid response among cataract patients. J Cataract Refract Surg. 2011;37:675\u201381.","journal-title":"J Cataract Refract Surg"},{"issue":"6","key":"401_CR40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41433-019-0616-7","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kuppermann BD, Bandello F, et al. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. Eye (Lond). 2020;34(6):1063\u20138.","journal-title":"Eye (Lond)"},{"issue":"4","key":"401_CR41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.survophthal.2020.01.002","volume":"65","author":"G Roberti","year":"2020","unstructured":"Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020;65(4):458\u201372.","journal-title":"Surv Ophthalmol"},{"key":"401_CR42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ajo.2007.04.021","volume":"144","author":"D Shukla","year":"2007","unstructured":"Shukla D, Vidhya N, Prasad NM, Mahalakshmi R, Kolluru C, Krishnadas R. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol. 2007;144:453\u20134.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"401_CR43","first-page":"720","volume":"62","author":"ME Cavet","year":"2021","unstructured":"Cavet ME, Sanfilippo CM, DeCory HH. Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate. Invest Ophthalmol Vis Sci. 2021;62(8):720.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"401_CR44","first-page":"720","volume":"62","author":"ME Cavet","year":"2021","unstructured":"Cavet ME, Sanfilippo CM, DeCory HH. Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate. Invest Ophthalmol Vis Sci. 2021;62(8):720. https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2774447","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"2","key":"401_CR45","doi-asserted-by":"crossref","first-page":"e00198","DOI":"10.1128\/mBio.00198-16","volume":"7","author":"H Shin","year":"2016","unstructured":"Shin H, Price K, Albert L, Dodick J, Park L, Dominguez-Bello MG. Changes in the eye microbiota associated with contact lens wearing. mBio. 2016;7(2):e00198.","journal-title":"mBio."},{"issue":"7","key":"401_CR46","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00417-021-05109-z","volume":"259","author":"P Vishwakarma","year":"2021","unstructured":"Vishwakarma P, Mitra S, Beuria T, Barik MR, Sahu SK. Comparative profile of ocular surface microbiome in vernal keratoconjunctivitis patients and healthy subjects. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1925\u201333.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"401_CR47","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1167\/iovs.12-9922","volume":"53","author":"SH Lee","year":"2012","unstructured":"Lee SH, Oh DH, Jung JY, Kim JC, Jeon CO. Comparative ocular microbial communities in humans with and without blepharitis. Invest Ophthalmol Vis Sci. 2012;53(9):5585\u201393.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"401_CR48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00003226-199110010-00010","volume":"10","author":"LR Groden","year":"1991","unstructured":"Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea. 1991;10:50\u20133.","journal-title":"Cornea"},{"issue":"5","key":"401_CR49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaophthalmol.2020.0155","volume":"138","author":"PA Asbell","year":"2020","unstructured":"Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in antibiotic resistance among ocular microorganisms in the United States from 2009 to 2018. JAMA Ophthalmol. 2020;138(5):439\u201350.","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-021-00401-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-021-00401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T20:44:18Z","timestamp":1699735458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-021-00401-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s40123-021-00401-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}